The daytime psychomotor performance of 12 healthy subjects of mean age 81.4 years was examined in a double-blind crossover study following single and repeated nightly doses of nitrazepam 5 mg, lormetazepam 1 mg, and placebo. Accuracy of performance on the Gibson spiral maze was unaffected by both dr
Residual effects of lormetazepam on mood and performance in healthy elderly volunteers
โ Scribed by J. B. Deijen; M. L. Heemstra; J. F. Orlebeke
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 548 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
โฆ Synopsis
45 subjects aged over 65 years were randomly assigned to treatment with lormetazepam 0.5 mg or 1 mg or placebo. Mood and performance were measured with a battery of computerized tests. Subjects were tested before and after 1 and 8 nights of treatment. Pre- and post-treatment scores were analysed by a multivariate covariance technique, the pre-treatment score serving as covariate. The single and repeated doses of lormetazepam resulted in impairment of performance in a memory task, and the repeated dose administration impaired performance of a perceptual task. The single administration of a low dose gave an improvement in fine motor control. No change was found in the mood states of the subjects.
๐ SIMILAR VOLUMES
One group of 10 young subjects were tested twice; in one test session 2 mg lormetazepam, in the other session placebo was administered, in random order. One subject dropped out. In one test session contractile force measurements were made six times; one measurement took place before treatment and th
The effects of moclobemide, a new selective and reversible MAO-A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or
## Abstract Brofaromine is a novel antidepressant that functions by the inhibition of the A form of monoamine oxidase (MAO). This inhibition is reversible, making brofaromine both pharmacologically and structurally different from most of the currently available MAO inhibitors. The drug has been sho